Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, 24 Week, Randomized, Open Label, Multi-Center Study to Assess the Safety, Tolerability, and Pharmacodynamics of FBS0701 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy, With a 72 Week Dosing Extension

NCT01186419 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT01186419
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01186419 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, 24 Week, Randomized, Open Label, Multi-Center Study to Assess the Safety, Tolerability, and Pharmacodynamics of FBS0701 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy, With a 72 Week Dosing Extension
Lead sponsor
Shire
Phase
Phase 2
Overall status
Completed
Start date
August 13, 2010
Completion date
January 8, 2013
Enrollment
51 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

beta-thalassemia, transfusional iron overload